Pharma major Cipla Ltd on Wednesday reported 55% year-on-year (YoY) decline in its consolidated net profit at Rs 555 crore in the fourth quarter, compared with Rs 1,222 crore in the last year quarter.
The Board has also recommended a final dividend of Rs 13 per share for the financial year ended March 2026. The record date for the purpose of payment of final dividend is June 5.
Revenue from operations in the reporting period decreased 3% YoY to Rs 6,541 crore.
EBITDA fell 35% to Rs 997 crore from Rs 1,538 crore in the year-ago period, while EBITDA margin contracted sharply to 15.2% from 22.8%.
For the full financial year FY26, Cipla reported revenue of Rs 28,163 crore, up 2% YoY, while annual PAT declined 26% to Rs 3,879 crore from Rs 5,273 crore in FY25. EBITDA for the year fell 17% to Rs 5,925 crore, with margin narrowing to 21% from 25.9% last year.
Cipla said its India business remained a key growth driver during the quarter. The One India business, which includes prescription, trade generics and consumer health operations, grew 15% year-on-year to Rs 3,007 crore in Q4 FY26 from Rs 2,622 crore a year ago.
The company said branded prescription therapies including respiratory, urology, anti-diabetes and cardiac segments continued to post strong growth, while consumer health brands such as Nicotex, Omnigel and Cipladine maintained leadership positions.
However, the North America business remained under pressure. Quarterly revenue from the region dropped 26% year-on-year to Rs 1,414 crore from Rs 1,919 crore. Despite the decline, the company highlighted regulatory approval for the first AB-rated generic version of gVentolin manufactured from its US facility.
The One Africa business continued to deliver strong growth momentum, with quarterly revenue rising 21% year-on-year to Rs 1,236 crore. South Africa revenue jumped 33% to Rs 984 crore.
Emerging Markets and Europe revenue declined 9% YoY to Rs 819 crore during the quarter amid geopolitical uncertainties, while API and other business revenue fell sharply by 77% to Rs 64 crore.
MD and Global CEO Achin Gupta said Cipla recorded its highest-ever annual revenue during FY26 despite near-term challenges in certain markets. He added that the company would continue focusing on flagship brands, pipeline investments and regulatory resolutions going forward.
On Wednesday, following the results announcement, Cipla shares were last trading 4% higher at Rs 1,344.9 on NSE.
